2026OCT 16
SAPA-GP · Philadelphia
Follow the Money: Capital Shaping Life Science AI
Panelist at the AI in Biopharma Executive Summit, exploring investment and capital formation around life sciences AI.
View official event program
Professional profile / Aaron Spivak
PhD MBA
Aaron Spivak.
Biotechnology Investor
& Scientist
Bringing a scientific perspective to biotechnology investing.
FocusBiotechnology investing
ResearchComputational biology
TrainingPhD & MBA
01 / About Aaron Spivak
Scientific training and investment experience, brought together.
Aaron Spivak is a biotechnology investor with a background in computational and systems biology. His experience spans public and private biotechnology investing, healthcare equity research, and drug discovery research. He works as a Senior Analyst at Balyasny Asset Management, which he joined in 2025 after serving as a Principal at Great Point Partners.
Earlier in his career, Aaron worked at JFL Capital Management and Palkon Capital Management. He began his professional career as a Scientific Investigator in Computational Biology at GlaxoSmithKline. His research has spanned computational genomics, combinatorial gene regulation, antibiotic resistance, and the application of quantitative methods to preclinical and clinical drug development.
Career and education: SAPA-GP speaker profile.
02 / Professional background
Experience & education.
Professional experience
- Balyasny Asset ManagementSenior Analyst · Joined 2025
- Great Point PartnersPrincipal
- JFL Capital ManagementSenior Investment Analyst
- Palkon Capital ManagementHealthcare Analyst
- GlaxoSmithKlineScientific Investigator, Computational Biology
Academic training
- Harvard Business SchoolMaster of Business Administration (MBA)
- Washington University in St. LouisPhD, Computational & Systems Biology
- Davidson CollegeBS, Biology
Board observer experience
Lycia Therapeutics
Served as a board observer while the company was privately held; stepped down upon its public listing.
03 / In conversation
Speaking & industry panels.
Recent discussions at the intersection of investment, innovation, and life sciences.
2026OCT 04
Cell & Gene Meeting on the Mesa · Phoenix
State of the Market: How Public Investors Value CGT Companies Today
Panelist at the Alliance for Regenerative Medicine CEO & Investor Summit, discussing public-market perspectives on cell and gene therapies.
View official event program04 / Published work
Selected scientific publications.
- 2018Nature Chemical Biology
Shared strategies for β-lactam catabolism in the soil microbiome
Microbiology · Antibiotic catabolism
- 2017Genome Announcements
Draft Genome Sequences of Three β-Lactam-Catabolizing Soil Proteobacteria
Microbiology · Genomics
- 2016G3: Genes, Genomes, Genetics
Combinatorial Cis-regulation in Saccharomyces Species
Computational biology · Gene regulation
- 2016European Respiratory Journal
Lung microbiome dynamics in COPD exacerbations
Microbiome · Respiratory disease
- 2015Antimicrobial Agents and Chemotherapy
Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections
Antibiotic resistance
- 2015PLOS ONE
Selective Spectrum Antibiotic Modulation of the Gut Microbiome in Obesity and Diabetes Rodent Models
Microbiome · Metabolic disease
- 2015Antimicrobial Agents and Chemotherapy
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase
Microbiome · Clinical research
- 2014PLOS ONE
Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus
Metabolic disease · Microbiome
- 2012Nucleic Acids Research
ScerTF: a comprehensive database of benchmarked position weight matrices for Saccharomyces species
Computational biology · Gene regulation
Explore the full scholarly profile: Google Scholar.
Continue the conversation
Find me online.
For professional background, publications, and industry conversations.